CRH:LSECRH public limited company Analysis
Data as of 2026-06-14 - not real-time
£8,790.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
CRH plc is trading at 8,790 GBp, comfortably above its 20‑day (7,682), 50‑day (8,241) and 200‑day (8,454) simple moving averages, yet technical gauges paint a mixed picture. The Relative Strength Index sits at a deep 10.1, flagging an oversold condition, while the MACD line remains negative with a bearish histogram, and the overall trend is flagged as bearish. Volume is on the rise and 30‑day volatility is exceptionally high at over 1,300%, suggesting sharp price swings may continue in the near term. Fundamentally, the company posted a 6.2% revenue increase to $37.4 bn, maintains a solid 10% profit margin and a 15.7% ROE, and generates healthy operating cash flow of $5.6 bn. However, its balance sheet is leveraged, with a debt‑to‑equity ratio of 77% and net debt far exceeding cash on hand. The valuation metrics are stark: a trailing P/E of 21.6, a price‑to‑book of 332×, and a DCF‑derived fair value of only $2,408 GBp place the stock well above intrinsic estimates, though analysts’ consensus of “strong buy” and a median target of $10,496 GBp imply an upside of roughly 18%. Recent news highlights a 9% Q1 revenue lift, a strategic push into U.S. water infrastructure, and the appointment of veteran CFO Aylwyn Bryan, all of which underpin the growth narrative.
Given the juxtaposition of an overvalued price, strong cash generation, and a favorable macro backdrop for infrastructure spending, the near‑term outlook is cautious, but the medium‑ to long‑term case remains anchored by sustainable earnings and dividend potential.
Given the juxtaposition of an overvalued price, strong cash generation, and a favorable macro backdrop for infrastructure spending, the near‑term outlook is cautious, but the medium‑ to long‑term case remains anchored by sustainable earnings and dividend potential.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Oversold RSI and rising volume suggest potential short‑term bounce
- Bearish MACD and trend indicator warn of further downside risk
- High volatility could amplify price swings
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 6.2% revenue growth and expanding margins support earnings expansion
- Strategic focus on U.S. water infrastructure aligns with global spending trends
- Analyst consensus of strong‑buy and ~18% upside target
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Sustainable dividend yield (1.27%) with a modest payout ratio
- Robust cash flow generation offsets leveraged balance sheet over time
- Valuation premium remains high, requiring continued earnings acceleration
Key Metrics & Analysis
Financial Health
Revenue Growth6.20%
Profit Margin10.02%
P/E Ratio21.6
ROE15.68%
ROA6.13%
Debt/Equity77.34
P/B Ratio332.3
Op. Cash Flow£5.6B
Free Cash Flow£1.8B
Technical Analysis
TrendBearish
RSI10.1
Support£84.16
Resistance£8,872.00
MA 20£7,682.40
MA 50£8,240.92
MA 200£8,454.24
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value£2,407.52
Target Price£10,343.40
Upside/Downside17.67%
GradeOvervalued
TypeGrowth
Dividend Yield0.01%
Risk Assessment
Beta0.78
Volatility1324.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.